Drug Effectiveness Review Project (DERP)

 Drug Effectiveness Review Project for pharmacy programs


Drug Effectiveness Review Project (DERP)

DERP is a trailblazing collaborative of state Medicaid and public pharmacy programs dedicated to producing comparative, evidence-based research products that assist policymakers and other decision-makers grappling with difficult drug coverage decisions.

Nationally recognized for its clinical objectivity and high-quality research, DERP focuses on specialty and other high-impact drugs— particularly those that have potential to change clinical practice. DERP reports evaluate efficacy, effectiveness, and safety of drugs to ultimately help improve patient safety and quality of care while helping government programs contain exploding costs for new therapies.

Recent DERP Reports

  • ADHD, Pharmacologic Treatments
  • Antipsychotics, Second Generation
  • Asthma & Chronic Obstructive Pulmonary Disease, Drugs to Treat
  • Diabetes Medications & Combinations, Newer
  • Direct Acting Antiviral Drugs for Hepatitis C
  • Injectable Oncology Drugs
  • Long-acting Insulins for Type 1 and Type 2 Diabetes
  • Long-acting Opioid Analgesics
  • Multiple Sclerosis, Disease-modifying Drugs
  • Oral Oncology Agents: Indications, Codes, NCCN
  • Guideline Recommendations & Payer Policies
  • Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) Inhibitors
  • Psychotropics in Children: Academic Detailing
  • Targeted Immune Modulators